TARE has become a mainstay of modern liver cancer care because of its unusual elegance. Rather than flooding the whole body with chemotherapy, clinicians deliver yttrium-90, a beta-emitting isotope bound to glass or resin microspheres roughly the width of a red blood cell, directly into the arteries that feed the tumor. The spheres lodge in the small vessels surrounding the malignancy and bathe it in high-dose radiation while sparing most healthy tissue. The technique works across the full spectrum of liver cancer severity, from early-stage disease where it can bridge patients to transplant, to advanced stages where it serves primarily to control tumor growth. Its safety record is genuinely impressive: serious adverse events occur in only about nine percent of patients, and vascular injury is estimated at no more than one percent of cases, typically arising when arterial anatomy is unusually complex, vessels have been weakened by prior chemotherapy, or pre-existing vascular abnormalities are present.

The Swiss case began conventionally enough. The patient, a man in his early seventies with liver fibrosis caused by chronic hepatitis C, was found on ultrasound to have a thirty-millimeter lesion in segment VIII of the liver, near the organ’s central hilum where major bile ducts and blood vessels converge. Magnetic resonance imaging and biopsy confirmed a moderately differentiated hepatocellular carcinoma, staged at an early BCLC stage with well-preserved liver function. A multidisciplinary tumor board weighed the options carefully. Percutaneous ablation, usually the first choice for small tumors, was judged too risky because of the lesion’s close proximity to a portal vein branch and the biliary tree. The team instead selected TARE, planning a curative dose of yttrium-90 glass microspheres engineered to deliver an estimated 324 gray to the perfused liver and more than a thousand gray to the tumor itself.

The workup phase went smoothly. Angiography revealed an anatomical quirk, a common hepatic artery arising from the superior mesenteric artery rather than its usual origin, but the team successfully navigated the tortuous route, advanced a microcatheter into the anterior sectoral artery supplying the tumor, and confirmed excellent targeting with technetium-99m-labeled macroaggregated albumin, the standard pre-treatment tracer. Two weeks later, during the therapeutic session, the trouble started. As the microcatheter was advanced along the same vessel, it caused a focal iatrogenic dissection, a tear in the arterial lining that separated the vessel wall into a true lumen and a false channel. Dissections of this kind are a recognized hazard of catheter work; guidelines from the Society of Interventional Radiology suggest they should prevent completion of the intended treatment in fewer than one percent of cases.

The team responded with textbook technique. They swapped the stiffer 2.7 French microcatheter for a softer, more flexible 1.98 French device paired with a fine guidewire, and successfully re-entered the true lumen. Digital subtraction angiography visualized the dissection, but selective intra-arterial CT angiography, a more detailed cross-sectional view taken from inside the vessel, showed no contrast stagnation in the false lumen, no pooling around the catheter tip, and preserved tumor enhancement that looked essentially identical to the simulation phase. Encouraged by these images, the physicians proceeded and administered 2.9 gigabecquerels of yttrium-90. Only afterward did post-treatment positron emission tomography reveal the flaw in that confidence: focal radioactive tracer uptake outside the liver tissue, in the region of the hepatic hilum, exactly where the dissection had occurred. Dosimetry calculations estimated that some 678 gray of radiation, an extraordinary dose by any standard, had pooled on the damaged arterial wall.

The critical insight, one the authors emphasize with some force, is that contrast dye is not a reliable proxy for microsphere behavior. Contrast agents and yttrium-90 spheres differ in particle size, density, and the way they move with blood flow, so a vessel that appears well perfused on angiography can still trap radioactive particles unevenly. In this patient, the dissection created abnormal flow conditions at the hepatic hilum that the intraprocedural imaging could not fully resolve. The spheres that should have been distributed throughout the tumor instead accumulated along an injured arterial wall, setting the stage for a form of collateral damage that is rarely reported and poorly understood: radiation-induced arteritis of the liver’s major vessels.

Because the patient remained symptom-free, he was discharged with daily telephone monitoring and a scheduled CT angiography seven days later, a deliberate precaution given the enormous extraparenchymal dose. That scan proved decisive. It revealed diffuse arteriopathy involving the common, right, and left hepatic arteries and their proximal branches, with multiple wall irregularities and three pseudoaneurysms, the largest measuring seven millimeters in the right hepatic artery. Pseudoaneurysms are balloon-like outpouchings formed when a weakened vessel wall balloons outward under pressure, and their rupture can trigger catastrophic intra-abdominal hemorrhage. The rapid onset of these changes, detectable within a single week, suggested a sinister synergy: mechanical injury from the catheter tearing the intima, compounded almost immediately by yttrium-90 radiation destroying the endothelial cells and muscular media of the vessel wall beneath.

The pathophysiology of radiation-induced vascular injury has been studied mostly in the context of external beam radiotherapy, where it is known to involve endothelial cell death, necrosis of the arterial media, and scarring of the adventitia that progressively narrows vessels or erodes them into aneurysms. Whether the same mechanisms unfold in the intrahepatic circulation after internal radiation has been largely uncharted territory. To the authors’ knowledge, no previous case has documented an iatrogenic arterial dissection during TARE evolving into subacute radiation-associated arteriopathy, which is precisely what makes the report valuable and unsettling. After urgent multidisciplinary consultation and shared decision-making with the patient, the team performed prophylactic coil embolization, deploying a series of detachable and pushable platinum coils through the hepatic arteries to pack shut the abnormal segments. Because the pathology was diffuse and multifocal, a covered stent, which would have preserved the vessel while sealing it, was not feasible, so the physicians accepted permanent sacrifice of the arterial tree. The patient’s preserved Child-Pugh A liver function and compensatory portal venous blood supply made the risk acceptable, though the team openly acknowledged a sobering trade-off: closing these arteries eliminated any possibility of future endovascular treatments if the cancer returned.

The outcome was, by any measure, a success story wrapped around a cautionary tale. Final angiography confirmed complete exclusion of the pseudoaneurysms and abnormal vessels, and transiently elevated liver enzymes normalized within five days. Magnetic resonance imaging at four weeks and three months showed a complete response of the original tumor by RECIST 1.1 criteria, with no biliary injury or hepatic ischemia, and preserved liver function throughout follow-up. A small new lesion in a distant segment was later treated successfully with percutaneous radiofrequency ablation. The authors distill the experience into several key lessons: anticipate vascular injury in patients with complex anatomy, reconsider microsphere delivery whenever arterial dissection occurs, maintain close post-procedural surveillance to catch vascular complications early, and weigh carefully whether definitive arterial embolization forecloses future treatment options. In asymptomatic patients, surveillance alone may suffice, since small pseudoaneurysms can stabilize or resolve, but their natural history is unpredictable and rupture can be lethal, so management must be individualized. For a procedure performed tens of thousands of times each year, this single case is a powerful reminder that even a one-percent risk deserves a protocol, and that the liver’s arteries, once injured and then irradiated, can fail in ways we are only beginning to describe.

Subject of Research: Iatrogenic arterial dissection during transarterial radioembolization leading to radiation-induced hepatic arteritis

Article Title: Iatrogenic arterial dissection leading to radiation induced arteritis following transarterial radioembolization

Article References: Adami, M., Boughdad, S., Villard, N., Schaefer, N., Rafael, D., & Tsoumakidou, G. (2026). Iatrogenic arterial dissection leading to radiation induced arteritis following transarterial radioembolization. CVIR Oncology, 2(1), Article 25. https://doi.org/10.1007/s44343-026-00061-3

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00061-3

Keywords: transarterial radioembolization, hepatocellular carcinoma, yttrium-90, arterial dissection, radiation-induced arteritis, hepatic artery, pseudoaneurysm, coil embolization, interventional radiology, dosimetry, vascular complication, case report

A new single-center retrospective study published in the European Journal of Nuclear Medicine and Molecular Imaging aims to change that. Researchers at Beijing Tsinghua Changgung Hospital analyzed 290 consecutive patients with unresectable hepatocellular carcinoma who underwent yttrium-90 selective internal radiation therapy between October 2022 and December 2025. Among them, 91 were flagged on pre-treatment imaging as potentially receiving tumor blood flow from the inferior phrenic artery, and 78 ultimately had angiographically confirmed supply from that vessel. The team then compared the two main ways interventional radiologists handle the artery: threading microspheres directly through it into the tumor, or deliberately plugging it with coils so that tumor blood flow is redirected back into the liver’s own arterial network.

The technical foundation of the study lies in meticulous pre-procedural mapping. Every patient underwent hepatic digital subtraction angiography combined with cone-beam computed tomography, a pairing that allows physicians to see not just the two-dimensional course of the vessels but the full three-dimensional territory each artery perfuses. A technetium-99m macroaggregated albumin injection followed by SPECT/CT simulation calculated the lung shunt fraction, ensuring that too many microspheres would not escape to the lungs, and post-treatment PET/CT verified where the radioactive spheres actually landed. Using a 2.1 French goose-neck microcatheter, the team achieved superselective catheterization of the inferior phrenic artery in 88.6 percent of attempted cases, demonstrating that even this small, tortuous vessel can be reliably accessed when combined angiographic and tomographic guidance is used.

The decision-making algorithm the researchers propose hinges on two variables: the volume of tumor fed by the inferior phrenic artery and the anatomy of any non-target branches that could carry microspheres into dangerous territory. When the artery perfused at least 20 milliliters of tumor and risky branches could be managed, the team favored direct infusion of yttrium-90 microspheres through the vessel, reserving prophylactic coil embolization for high-risk offshoots such as suprarenal, esophageal, pericardial, or pulmonary shunt branches. When the perfused tumor volume fell below 20 milliliters or non-target vessels could not be safely catheterized, the team simply embolized the artery trunk with coils, wagering that intrahepatic arteries would compensate. Forty-five patients landed in the infusion group and 33 in the embolization group, with the infusion cohort predictably carrying heavier tumor burdens and more advanced disease.

The anatomical findings reinforce how distinctive the inferior phrenic artery can be. The right inferior phrenic artery dominated as the parasitic feeding vessel in 89.8 percent of cases, with the left artery accounting for only 7.7 percent and dual supply appearing in 2.5 percent. Most of these arteries originated from the celiac trunk or directly from the abdominal aorta, though a striking 21.8 percent arose from the renal artery. The median radioactivity delivered through the inferior phrenic artery was a modest 0.3 gigabecquerels, yet the dosimetric payoff was substantial: the median tumor-absorbed dose in the infusion group reached 92 Gy, with three-quarters of those patients receiving at least 61 Gy, approaching the 100 to 250 Gy window widely recommended for hepatocellular carcinoma.

Perhaps the most eye-catching result concerns the embolization strategy, which has always rested on an assumption that had never been carefully quantified. If you plug the parasitic artery, does tumor blood flow really reroute to intrahepatic vessels in time to matter? By comparing intra-procedural cone-beam CT with post-treatment PET/CT, the researchers found that approximately 88 percent of the territory originally supplied by the inferior phrenic artery received yttrium-90 microspheres through compensatory intrahepatic pathways, with more than half of lesions achieving complete hemodynamic compensation. Critically, the compensatory rate held steady regardless of tumor size, suggesting that flow redistribution after coil embolization is a robust phenomenon rather than a fortunate accident, and providing quantitative reassurance comparable to the 83.8 percent redistribution rate previously reported with glue embolization.

On efficacy, direct infusion through the inferior phrenic artery consistently outperformed embolization. Using the modified Response Evaluation Criteria in Solid Tumors, the objective response rate in the infusion group climbed from 60.0 percent at one month to 82.3 percent at three months, whereas the embolization group moved from 48.5 percent to 69.7 percent over the same intervals. The gap between the groups widened to 12.6 percentage points by three months, and the complete response rate in the infusion group surged from 17.8 percent to 46.7 percent, an absolute gain of 28.9 percentage points that far outpaced the 21.2 percent rise seen in the embolization cohort. Disease control rates exceeded 93 percent at one month in both groups, underscoring that neither strategy leaves patients behind.

Safety is where lingering fears about extrahepatic radiation have historically been most vocal, and the study directly confronts them. Mean whole-lung absorbed dose was 9.53 Gy, comfortably below the 20 Gy clinical threshold, with no significant differences between groups in lung volume, lung shunt fraction, or lung dose. The overall adverse event rate was 17.8 percent in the infusion group and 9.1 percent in the embolization group, a difference that was not statistically significant, and every reported event was a mild to moderate, reversible thoracic complaint. No severe treatment-related complications occurred in either arm, an outcome the authors attribute to the discipline of combined DSA-CBCT anatomical evaluation paired with prophylactic embolization of non-target branches whenever they were visualized.

The study’s authors are candid about its limits. As a single-center retrospective analysis, it carries inherent selection bias, and the infusion group’s higher tumor burden and greater proportion of Barcelona Clinic Liver Cancer stage C patients may confound the efficacy comparison. Only three-month tumor response was assessed, leaving progression-free survival and overall survival unmeasured, and the team calls for long-term follow-up and multicenter prospective validation before the algorithm becomes standard practice. Even so, the work represents the largest head-to-head comparison of inferior phrenic artery strategies in yttrium-90 radioembolization to date, and it delivers something the field has lacked: a concrete, volume-based decision rule. Direct infusion when the artery feeds at least 20 milliliters of tumor and the plumbing cooperates; embolization when it does not. For the roughly one in three hepatocellular carcinoma patients whose tumors recruit this diaphragmatic artery, that clarity could mean the difference between an incomplete treatment and a truly definitive one.

Subject of Research: Inferior phrenic artery management strategies during yttrium-90 selective internal radiation therapy for hepatocellular carcinoma.

Article Title: Interventional strategies for inferior phrenic artery management in yttrium‑90 selective internal radiation therapy for hepatocellular carcinoma: A single‑center retrospective study

Article References: Liao, Y., Huang, X., Liang, Z., Ma, J., Feng, X., Fu, W., Liang, B., Yang, S., Li, G., Bao, L., Zhang, T., Zheng, L., Liu, C., Tang, M., Zhang, L., & Dong, J. (2026). Interventional strategies for inferior phrenic artery management in yttrium‑90 selective internal radiation therapy for hepatocellular carcinoma: A single‑center retrospective study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08170-0

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08170-0

Keywords: yttrium-90, selective internal radiation therapy, hepatocellular carcinoma, inferior phrenic artery, radioembolization, interventional radiology, cone-beam computed tomography, lung shunt fraction, mRECIST, extrahepatic collateral supply, tumor response, coil embolization